Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Stomach Neoplasms 4Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × rilotumumab × Clear all
NCT02137343 2016-04-04

RILOMET-2

Amgen

Phase 3 Terminated
34 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01791374 2016-02-29

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Amgen

Phase 1 Completed
21 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01697072 2016-02-09

RILOMET-1

Amgen

Phase 3 Terminated
609 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00719550 2013-12-05

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Amgen

Phase 1/2 Completed
130 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡